Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment

Prostate

Volumn 28, Issue 5, 1996, Pages 282-286

  Maffezzini, Massimo ^a,c   Simonato, Alchiede ^a   Fortis, Claudio ^b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Hormone refractory prostatic cancer; Interferon; Interleukin

Indexed keywords

ALPHA INTERFERON; ESTRAMUSTINE PHOSPHATE; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEVER; HUMAN; INFLUENZA; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT FAILURE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ESTRAMUSTINE; HUMANS; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; INTERLEUKIN-10; INTERLEUKIN-2; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0029917710     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(199605)28:5<282::AID-PROS2>3.0.CO;2-E     Document Type: Article

References (23)

1. Trachtemberg J, Walsh PC: Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer. J Urol 127:466-469, 1982.
2. de Kernion JN, Murphy GP, Priore R: Comparison of flutamide and emcyt in hormone refractory prostatic cancer. Urology 31:312-317, 1988.
3. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3:827-841, 1985.
4. Eisemberg MA: Chemotherapy for prostate carcinoma. NCI Monogr 7:151-163, 1988.
5. Rosemberg SA, Lotze MT, Mulè JJ: New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med 108:853-864, 1988.
6. Rosemberg SA, Lotze MT, Yang JC, Aebersold PM, Linehann WM, Seipp CA, White DE: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474-485, 1989.
7. West WH, Tauer KW, Jannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898-905, 1987.
8. Lee RE, Lotze MT, Skibber JM, Ticker E, Bonow RO, Ognibene FP, Carrasquillo JA, Shelhamer JH, Parrillo JE, Rosemberg SA: Cardiordiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 7:7-20, 1989.
9. Atzpodien J, Korfer A, Franks CR, Poliwoda H, Kirchner H: Home therapy with recombinant interleukin-2 and interferon-alpha2b in advanced human malignancies. Lancet 335:1509-1512, 1990.
10. Clementi E, Bucci E, Citterio G, Landonio G, Consogno G, Fortis C: Reversible anergy in circulating lymphocytes of cancer patients during interleukin-2 therapy. Cancer Immunol Immunother (in press).
11. Ades EW, Bosse D, Orr S, Gillespie T: Immune responses in humans while receiving adoptive immunotherapy with recombinant interleukin-2 and lymphokine activated killer cells: Acute anergy to mitogens and recall antigens. Pathobiology 58:78-83, 1990.
12. Fiorentino DF, Zlotnik A, Veira P, Mosmann TR, Howard M, Moore KW, O'Garra A: IL-10 acts on the antigen presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146:3444-3451, 1991.
13. Powrie F, Menon S, Coffman RL: Interleukin-4 and interleukin-10 synergize to inhibit cell mediated immunity in vivo. Eur J Immunol 23:3043-3049, 1993.
14. Howard M, O'Garra A, Ishida H, De Waal Malefyt R, De Vries J: Biological properties of interleukin-10. J Clin Immunol 12:239-247, 1992.
15. Murphy GP, Slack NH: Response criteria for the prostate of the USA National Prostatic Cancer Project. Prostate 1:375-378, 1980.
16. Manni A, Santen RJ, Boucher AE, Liton A, Harvey H, Simmonds M, White-Hershey D, Gordon RA, Rohner TJ, Drago J, Wettlaufer J, Glode LM: Androgen priming and response to chemotherapy in advanced prostatic cancer. J Urol 136:1242-1246, 1986.
17. Sica G, Fabbroni L, Castagnetta L, Cacciatore M, Pavone Macaluso M: Antiproliferative effect of interferons on human prostate carcinoma cell lines. Urol Res 17: 111-115, 1989.
18. Fidler IJ, Heicappel R, Saik I, Grutter MG, Horisberger MA, Nuech J: Direct antiproliferative effects of recombinant human interferons alpha B/D hybrids on human tumor cell lines. Cancer Res 47:2020-2024, 1987.
19. Bulbul MA, Huben RP, Murphy GP: Interferon beta treatment of metastatic prostate cancer. J Surg Oncol 33:231-233, 1986.
20. Chang AYC: Toxicities of human recombinant alpha 2 in patients with advanced prostate carcinoma. J IFN Res 6:713-716, 1986.
21. Cameron RB, McIntosh JK, Rosemberg SA: Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and recombinant hybrid interferon alpha in the treatment of established murine hepatic metastases. Cancer Res 48:5810-5817, 1988.
22. Scher HI, Kelly WK: Flutamide withdrawal syndrome: Its impact on clinical trials in hormone refractory prostate cancer. J Clin Oncol 11:1566-1572, 1993.
23. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Cofman RL: Two types of murine helper T cell clones. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348-2357, 1986.